Nortriptyline Hydrochloride
Phase 3Small molecule
Nortriptyline Hydrochloride is one of 61 small molecule programs targeting Small Cell Carcinoma. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Gastroparesis
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Zelnorm
AAlfasigma S.p.A.
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Haldol
DDePuy Orthopaedics
Approved
Relistor
SSalix
Approved
Kytril
CConrado Roberto Hoffmann Filho
Approved
Pitocin
RRetrophin
Approved
Resotran
TakedaPhase 3
Mosapride
SSeoul National University Hospital
Approved
Nereus
VVanda Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastroparesis1 trial
Nortriptyline for Idiopathic Gastroparesis
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00765895·130 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nortriptyline Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details